Next Article in Journal
Hypoxia-Induced Extracellular Vesicles and Non-Coding RNAs in Cancer: A Systematic Review of Tumor Dynamics and Therapeutic Implications in Preclinical Animal Models
Previous Article in Journal
Longitudinal Effects of Bilateral Subthalamic Nucleus Deep Brain Stimulation Versus Best Medical Therapy on Static and Dynamic Balance and Gait in Advanced Parkinson’s Disease: A 36-Month Comparative Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 13
Issue 11
10.3390/biomedicines13112795
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Biomedicines 2023, 11(4), 1064.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Ahmad et al. Formulation and Optimization of Repaglinide Nanoparticles Using Microfluidics for Enhanced Bioavailability and Management of Diabetes. Biomedicines 2023, 11, 1064

by
Mubashir Ahmad
1,
Shahzeb Khan
2,
Syed Muhammad Hassan Shah
3,
Muhammad Zahoor
4,
Zahid Hussain
5,6,
Haya Hussain
7,
Syed Wadood Ali Shah
1,*,
Riaz Ullah
8 and
Amal Alotaibi
9
1
Department of Pharmacy, University of Malakand, Chakdara 18800, Pakistan
2
Center for Pharmaceutical Engineering Science, Faculty of Life Sciences, School of Pharmacy and Medical Sciences, University of Bradford, Bradford BD7 1DP, UK
3
Department of Pharmacy, Sarhad University of Science and Information Technology, Peshawar 18500, Pakistan
4
Department of Biochemistry, University of Malakand, Chakdara 18800, Pakistan
5
Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates
6
Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates
7
Department of Pharmacy, Shaheed Benazir Bhutto University, Sheringal Dir 18000, Pakistan
8
Medicinal Aromatic and Poisonous Plants Research Center, Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
9
Department of Basic Science, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia
*
Author to whom correspondence should be addressed.
Biomedicines 2025, 13(11), 2795; https://doi.org/10.3390/biomedicines13112795
Submission received: 3 October 2025 / Accepted: 4 November 2025 / Published: 17 November 2025
(This article belongs to the Section Nanomedicine and Nanobiology)
Browse Figure
Versions Notes

Error in Figure

In the original publication, there was an inadvertent labeling mistake in Figure 11A as published [1]. Figure 11A was mistakenly mislabeled as corresponding to the control group. In fact, it is a second image from the Rp-Nc 1 mg-treated group. This image was captured from the same sample as that shown in Figure 11D. As a result, there is a slight overlap in one corner of Figure 11A,D, since both represent the same treatment group. Because we were capturing images from different parts of the organs, unintentional mislabeling occurred. The corrected version of Figure 11 appears below.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Ahmad, M.; Khan, S.; Shah, S.M.H.; Zahoor, M.; Hussain, Z.; Hussain, H.; Shah, S.W.A.; Ullah, R.; Alotaibi, A. Formulation and Optimization of Repaglinide Nanoparticles Using Microfluidics for Enhanced Bioavailability and Management of Diabetes. Biomedicines 2023, 11, 1064. [Google Scholar] [CrossRef] [PubMed]
Biomedicines 13 02795 g011
Figure 11. Photomicrographs of microsections of the pancreas of rats: (A) control group showing the normal histological structure of islets of Langerhans with normal pancreatic acini; (B) diabetic group showing ruptured and destroyed islets of Langerhans with damage in beta cells; and (C,D) Rp-Nc 0.5 mg- and 1 mg-treated groups showing some normal islets of Langerhans with some mild destruction in normal pancreatic ducts and in between normal pancreatic acini (H&E scale bar, 25 µm).
Figure 11. Photomicrographs of microsections of the pancreas of rats: (A) control group showing the normal histological structure of islets of Langerhans with normal pancreatic acini; (B) diabetic group showing ruptured and destroyed islets of Langerhans with damage in beta cells; and (C,D) Rp-Nc 0.5 mg- and 1 mg-treated groups showing some normal islets of Langerhans with some mild destruction in normal pancreatic ducts and in between normal pancreatic acini (H&E scale bar, 25 µm).
Biomedicines 13 02795 g011
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ahmad, M.; Khan, S.; Shah, S.M.H.; Zahoor, M.; Hussain, Z.; Hussain, H.; Shah, S.W.A.; Ullah, R.; Alotaibi, A. Correction: Ahmad et al. Formulation and Optimization of Repaglinide Nanoparticles Using Microfluidics for Enhanced Bioavailability and Management of Diabetes. Biomedicines 2023, 11, 1064. Biomedicines 2025, 13, 2795. https://doi.org/10.3390/biomedicines13112795

AMA Style

Ahmad M, Khan S, Shah SMH, Zahoor M, Hussain Z, Hussain H, Shah SWA, Ullah R, Alotaibi A. Correction: Ahmad et al. Formulation and Optimization of Repaglinide Nanoparticles Using Microfluidics for Enhanced Bioavailability and Management of Diabetes. Biomedicines 2023, 11, 1064. Biomedicines. 2025; 13(11):2795. https://doi.org/10.3390/biomedicines13112795

Chicago/Turabian Style

Ahmad, Mubashir, Shahzeb Khan, Syed Muhammad Hassan Shah, Muhammad Zahoor, Zahid Hussain, Haya Hussain, Syed Wadood Ali Shah, Riaz Ullah, and Amal Alotaibi. 2025. "Correction: Ahmad et al. Formulation and Optimization of Repaglinide Nanoparticles Using Microfluidics for Enhanced Bioavailability and Management of Diabetes. Biomedicines 2023, 11, 1064" Biomedicines 13, no. 11: 2795. https://doi.org/10.3390/biomedicines13112795

APA Style

Ahmad, M., Khan, S., Shah, S. M. H., Zahoor, M., Hussain, Z., Hussain, H., Shah, S. W. A., Ullah, R., & Alotaibi, A. (2025). Correction: Ahmad et al. Formulation and Optimization of Repaglinide Nanoparticles Using Microfluidics for Enhanced Bioavailability and Management of Diabetes. Biomedicines 2023, 11, 1064. Biomedicines, 13(11), 2795. https://doi.org/10.3390/biomedicines13112795

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop